Current status of castration-resistant prostate cancer translational research
Maeno, A.; Habuchi, T.
Nihon Rinsho. Japanese Journal of Clinical Medicine 74(1): 40-44
2016
ISSN/ISBN: 0047-1852 PMID: 26793877 Document Number: 688303
Recently, new drugs including abiraterone and enzalutamide have been able to be used for castration resistant prostate cancer(CRPC) patients. However, a subset of these patients who receive the new drugs does not response to the therapies. Furthermore, most patients who initially response to the drugs, progress to secondary resistance eventually. Therefore, it is important to investigate a novel therapeutic target and a novel treatment-selection marker for CRPC. In this review, we focused on AR-V7, TMPRSS2-ERG fusion gene and EP4 antagonist as representative translational researches.